- Home
- ARQT vs PLMR Comparison
ARQT vs PLMR Comparison
Compare ARQT & PLMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- PLMR
- Stock Information
- Founded
- ARQT 2016
- PLMR 2013
- Country
- ARQT United States
- PLMR United States
- Employees
- ARQT N/A
- PLMR N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- PLMR Property-Casualty Insurers
- Sector
- ARQT Health Care
- PLMR Finance
- Exchange
- ARQT Nasdaq
- PLMR Nasdaq
- Market Cap
- ARQT 3.3B
- PLMR 3.0B
- IPO Year
- ARQT 2020
- PLMR 2019
- Fundamental
- Price
- ARQT $28.01
- PLMR $126.26
- Analyst Decision
- ARQT Strong Buy
- PLMR Buy
- Analyst Count
- ARQT 7
- PLMR 8
- Target Price
- ARQT $22.17
- PLMR $154.71
- AVG Volume (30 Days)
- ARQT 3.1M
- PLMR 260.0K
- Earning Date
- ARQT 10-28-2025
- PLMR 11-06-2025
- Dividend Yield
- ARQT N/A
- PLMR N/A
- EPS Growth
- ARQT N/A
- PLMR 51.73
- EPS
- ARQT N/A
- PLMR 6.40
- Revenue
- ARQT $317,929,000.00
- PLMR $778,362,000.00
- Revenue This Year
- ARQT $85.27
- PLMR $255.68
- Revenue Next Year
- ARQT $30.70
- PLMR $19.34
- P/E Ratio
- ARQT N/A
- PLMR $19.60
- Revenue Growth
- ARQT 129.21
- PLMR 54.59
- 52 Week Low
- ARQT $9.19
- PLMR $98.42
- 52 Week High
- ARQT $28.96
- PLMR $175.85
- Technical
- Relative Strength Index (RSI)
- ARQT 71.06
- PLMR 57.25
- Support Level
- ARQT $22.26
- PLMR $127.60
- Resistance Level
- ARQT $24.39
- PLMR $130.80
- Average True Range (ATR)
- ARQT 1.46
- PLMR 3.84
- MACD
- ARQT 0.21
- PLMR 0.80
- Stochastic Oscillator
- ARQT 85.67
- PLMR 62.24
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About PLMR Palomar Holdings Inc. Common stock
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. provide insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The companies Earthquake product generate high premium.